Guest Editors
Dr. ZHANG-YIN Jules
Email: jules.zhangyin@vivalia.be
Affiliation: Nuclear Medicine Department, Clinique Sud Luxembourg, Arlon, Belgium
Homepage:
Research Interests: prostate cancer imaging, PET hybrid imaging, theranostics and radiopharmaceuticals, radiomics and artificial intelligence in oncology
Summary
Prostate cancer is the most frequently diagnosed solid tumor in men and remains a major global healthcare concern. Precise imaging is critical both at the time of initial diagnosis and during biochemical recurrence (BCR), as accurate lesion detection directly influences clinical decision-making. This Special Issue aims to highlight recent advances in multimodal imaging for both localized prostate cancer and BCR, including innovative integrations of PET/CT, PET/MRI, multiparametric MRI (mpMRI), and ultrasound fusion techniques. The use of PSMA-targeted PET imaging and emerging radiotracers offers unparalleled sensitivity in identifying disease foci, even at low PSA levels. At the same time, machine learning and radiomics are enabling personalized risk stratification and treatment optimization.
Topics of interest include:
-PSMA PET/CT and PET/MRI for initial staging and BCR
-Radiomics and AI in prostate cancer imaging
-Advances in multiparametric MRI
-PET-based response assessment after radiotherapy or surgery
-Imaging-guided focal therapies and biopsy
-Novel PET tracers beyond PSMA (e.g., GRPR, FAPi)
-Decision-making algorithms incorporating imaging data
-Cost-effectiveness and clinical utility of advanced imaging
This issue invites original research, technical advances, comprehensive reviews, and translational research perspectives.
Keywords
prostate cancer, biochemical recurrence, PSMA PET/CT, mpMRI, PET/MRI, radiomics, artificial intelligence, focal therapy
Login
Register
Submit a Paper
Propose a Special lssue